Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05957276 · ClinicalTrials.gov registry record
Global Patient Registry of Inherited Retinal Diseases
A clinical trial of Inherited Retinal Diseases, sponsored by Janssen Research & Development.
- Active
- Registry status
- 891
- Enrollment target
- 20
- Study locations
NCT05957276: Active study of Inherited Retinal Diseases, sponsored by Janssen Research & Development.
NCT05957276 is a study of Inherited Retinal Diseases that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 891 participants. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05957276, a study of Inherited Retinal Diseases, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- 891 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.
Primary Outcome
VA is a measure of the sharpness of vision. The test uses a chart with letters or symbols of different sizes, at a specific distance, and is reported using various scales, such as fraction, decimal, minimum angle of resolution (MAR), logMAR. When a participant is unable to read a chart, visual acuity can be measured by counting fingers, hand motion, or light perception.
Conditions Studied
Interventions
- OTHER Standard of Care
Study Locations (20)
Texas
- Retina Consultants of Texas - Bellaire
- Baylor College of Medicine - Houston
- University of Texas Houston - Houston
California
- University of Southern California - Los Angeles
- UCSF - San Francisco
Other
- Centre for Eye Research Australia - East Melbourne
- Lions Eye Institute - Nedlands
Alabama
- University of Alabama Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Florida
- Bascom Palmer Eye Institute - Miami
Georgia
- Emory University - Atlanta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 891 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2026-07-03 |
What the registry record for NCT05957276 still lists
NCT05957276 is an observational study that tracks outcomes without assigning an intervention. The registered 891 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Inherited Retinal Diseases appearing as the primary indexed condition, and to 1 intervention - of which Standard of Care is the first listed.
NCT05957276 names 20 study sites across 16 states, led by Texas, California, Other.
Frequently Asked Questions
What is clinical trial NCT05957276 about?
NCT05957276 is a clinical study titled "Global Patient Registry of Inherited Retinal Diseases". The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.
What is the current status of trial NCT05957276?
This trial is currently active not recruiting. The enrollment target is 891 participants. The study started on 2023-08-31. Estimated completion is 2026-07-03.
What conditions does trial NCT05957276 study?
This clinical trial studies the following conditions: Inherited Retinal Diseases.
What interventions are being tested in trial NCT05957276?
The interventions under investigation include: Standard of Care (OTHER).
Who is sponsoring clinical trial NCT05957276?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05957276 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inherited Retinal Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI